Business
Seres Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results and Corporate Highlights
– Data-rich period ahead including two expected late-stage microbiome clinical readouts: SER-109 in recurrent C. difficile infection in mid-2020 and SER-287
About this update from Seres Therapeutics, Inc.
[{"type":"text","content":"\n– Data-rich period ahead including two expected late-stage microbiome clinical readouts: SER-109 in recurrent C. difficile infection in mid-2020 and SER-287 for ulcerative colitis in H2 2020 –\n\n\n– Clinical development activities initiated for SER-301, a next-generation, rationally designed product candidate for ulcerative colitis –\n\n\n– Approximately $100M of new capital raised in 2019; Company well funded for multiple anticipated upcoming clinical study readouts –\n\n\n– Conference call at 8:30 a.m. ET today; Presentation at Cowen conference at 1:30 p.m. ET today –\n\n CAMBRIDGE, Mass.--(BUSINESS WIRE)--\nSeres Therapeutics, Inc., (Nasdaq: MCRB) today reported fourth quarter and full year 2019 financial results and provided an operational update.\n\n\n“Throughout 2019, we reinforced Seres’ leadership in microbiome therapeutics and advanced our robust pipeline toward multiple near-term readouts and secured an immuno-oncology collaboration with AstraZeneca. We also strengthened our balance sheet by adding approximately $100 million of new capital to support our R&D programs through important milestones expected in 2020, including two late stage clinical readouts,” said Eric Shaff, President and Chief Executive Officer of Seres. “We are excited by the potential of SER-287 for ulcerative colitis and SER-109 for recurrent C. difficile infection. Both of these therapeutic candidates could represent first-in-class treatments with potential to fundamentally transform disease management. These readouts may also serve to further validate the tremendous promise of our microbiome therapeutics approach.”\n\n\nMr. Shaff continued: “We have been steadfast in our commitment to completing a rigorous SER-109 Phase 3 study in a well-defined patient population and using an objective endpoint in order to generate valid, clinically meaningful study results. We are pleased that the ECOSPOR III study is nearly fully enrolled and we eagerly look forward to results in the middle of this year.”\n\n\nProgram and Corporate Updates\n\n\nSER-109 Phase 3 ECOSPOR III study in recurrent C. difficile infection: SER-109 is an orally-administered, biologically-derived, live microbiome therapeutic candidate designed to restore the depleted, or dysbiotic, gastrointestinal microbiome of patients with recurrent C. difficile infection. Seres’ SER-109 manufacturi...